Le comité d'experts sélectionne régulièrement les dernière publications les plus pertinentes pour une lecture rapide. Cela comprend un bref résumé mettant en évidence les points clés de l'article et un jeu de diapositives pour rentrer dans plus de détails sur les données.
Cytokine Signalling Forum
Latest Podcasts
Author Interview: Professor Peter Taylor
Professor Peter Taylor, from the University of Oxford in the UK.
28th April 2022
Discussing Rheumatology: Pain, pneumonia and perspectives
Prof Iain McInnes reviews three papers this month!
28th April 2022
Discussing Rheumatology Podcast March 2022
Prof Iain McInnes reviews two papers this month, both focusing on JAKi and Rheumatoid Arthritis
12th April 2022
Author Interview: Professor Roy Fleischmann – March 2022
Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center.
16th March 2022
Author Interview: Professor Rüdiger Müller
Professor Rüdiger Müller, Rheumazentrum Ostschweiz, Switzerland
24th February 2022
Discussing Rheumatology: Tofacitinib safety and dose-switching in RA
Prof Iain McInnes reviews two papers this month, both on tofacitinib. The first looks at CV outcomes from the STAR-RA study, the second is a post-hoc analysis of ORAL Sequel looking into tofacitinib dose switching.
24th February 2022
ORAL Surveillance Author Interview – Roy Fleischmann
Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center.
09th February 2022
Author Interview: Professor Kevin Winthrop (January 2022)
Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University.
03rd February 2022
Discussing Rheumatology: HZ and ILD with tofacitinib in RA
Prof Iain McInnes reviews two papers this month, and discusses the risk of herpes zoster (HZ) events in patients with RA treated with tofacitinib, as well as interstitial lung disease, an extra-articular manifestation of RA.
27th January 2022
Discussing Rheumatology: Safety of filgotinib, and tofacitinib in pJIA
Prof Iain McInnes reviews two papers this month, and discusses exposure-adjusted incidence rates of TEAEs and AESIs with filgotinib, as well as the efficacy and safety of tofacitinib in pJIA.
23rd December 2021
Author Interview: Professor Kevin Winthrop (December 2021)
Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University.
23rd December 2021
Author Interview: Professor Kevin Winthrop (November 2021)
Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University.
22nd December 2021
Author Interview: Professor Atul Deodhar
Professor Atul Deodhar, professor of medicine at Oregon Health & Science University.
06th December 2021
Discussing Rheumatology: Risk of HZ with UPA, and JAKs in SpA
Prof Iain McInnes reviews two papers this month, and discusses the increased risk of HZ infection with upadacitinib, as well as the role of the JAK-STAT pathway in SpA pathenogenesis.
06th December 2021
Author Interview: Professor Roy Fleischmann
Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center.
18th November 2021
Discussing Rheumatology: Herpes Zoster and HBV
Prof Iain McInnes discusses the risk of herpes zoster in RA patients taking biologics and DMARDS. He also discusses reactivation of hepatitis B in patients with RA taking tofacitinib.
31st October 2021
Rheumatology Author Professor Paul Bird: Tofacitinib Effectiveness
Paul Bird, Conjoint Professor at the University of South Wales joins Professor Peter Nash, where he discusses real-world data of tofacitinib therapy in RA
15th October 2021
Discussing Rheumatology: Poor Prognostic Factors, Monotherapy, and Combination Therapy
Prof Iain McInnes discusses poor prognostics factors from the FINCH 3 study, and the effectiveness and persistence of monotherapy and combination therapy from the Australian OPAL study.
23rd September 2021
